At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Ifetroban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease
In Brief
A Phase 2 clinical trial evaluating Ifetroban and Placebo for Nasal Polyps and 3 related conditions. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartApr 2018
Primary CompletionMar 2022
Study CompletionApr 2023
TodayJul 2026
First PostedOct 30, 2017
Enrollment StartApr 26, 2018
Primary CompletionMar 30, 2022
Study CompletionApr 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.7 years ago
Interventions
Ifetrobandrug
4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Placebodrug
4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD